GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » EPS (Diluted)

Core One Labs (XCNQ:COOL) EPS (Diluted) : C$-0.05 (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs EPS (Diluted)?

Core One Labs's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was C$-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.05.

Core One Labs's EPS (Basic) for the three months ended in Dec. 2023 was C$-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.05.

Core One Labs's EPS without NRI for the three months ended in Dec. 2023 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was 35.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Core One Labs's highest 3-Year average EPS without NRI Growth Rate was 59.10% per year. The lowest was -13.00% per year. And the median was 8.45% per year.


Core One Labs EPS (Diluted) Historical Data

The historical data trend for Core One Labs's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs EPS (Diluted) Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.24 -10.56 -15.36 -10.30 -2.57

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.04 -0.01 -0.03 -0.02

Competitive Comparison of Core One Labs's EPS (Diluted)

For the Biotechnology subindustry, Core One Labs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's PE Ratio distribution charts can be found below:

* The bar in red indicates where Core One Labs's PE Ratio falls into.



Core One Labs EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Core One Labs's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-37.055-0)/14.420
=-2.57

Core One Labs's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.841-0)/44.882
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Core One Labs  (XCNQ:COOL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Core One Labs EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Core One Labs's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.